ADVIA Centaur CA 125II
by Siemens Healthcare Diagnostics, Inc.
510(k) K200199Ref 10310443Model IVDR_67_TTN_DUB-C_C_KIT_CA 125II
Active
Valid until
Not listed
FDA recalls
None foundTrust
Unverified
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| European Union | CE/IVDR EUDAMED | Number0405686901800VJ 00630414461298 | Date29 May 2026 | StatusActive |
| United States | FDA 510(k)SESE 510(k) | NumberK200199 | Date6 Apr 2020 | StatusActive |
| United States | GUDID listing GUDID | Number00630414461298 | Date24 Sep 2016 | StatusListed |
Certificates
EUDAMED lists no certificate for this device's Basic UDI-DI.
Recalls
No FDA recalls found in the data synced 7 Oct 2026.
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
- European Union
- United States
Specification
- Generic Name
- Cancer antigen 125 (CA125) IVD, kit, chemiluminescent immunoassay
- Device Name
- IVDR_67_TTN_DUB-C_c_kit_ca 125II
- Model / Ref / Catalog
- 10310443, IVDR_67_TTN_DUB-C_C_KIT_CA 125II, 128532
- Primary DI / UDI-DI
- 00630414461298
- Basic UDI-DI
- 0405686901800VJ
- 510(k) Number
- FDA Product Code
- LTK
- EMDN Code
- W0102030106 Cancer antigen 125
- GMDN Term
- Cancer antigen 125 (CA125) IVD, kit, chemiluminescent immunoassay
- Device Class
- Class C EUDAMEDClass II 510(k)GUDID
- Regulation
- 21 CFR Part 866.6010
- EU market of registration
- Germany
- Advisory Committee
- Immunology
- FDA Decision
- SESE Substantially Equivalent
- GUDID distribution status
- In Commercial Distribution
Truth per registry
| Field | EUDAMED | 510(k) | GUDID |
|---|---|---|---|
| Device Class | Class C | Class II | Class II |
Overview
AI-generated summary, 18 Sep 2026
The ADVIA Centaur CA 125II is an in vitro diagnostic immunoassay device (Regulation Number 866.6010) designed for the quantitative measurement of CA 125 (Epithelial Ovarian Tumor-Associated Antigen) in human serum and plasma (EDTA or lithium heparin). It employs a sandwich immunoassay with direct chemiluminescence technology, utilizing OC 125 and M11 antibodies for capture and signal detection, respectively. This second-generation assay is intended to improve diagnostic reliability for monitoring ovarian carcinoma.
The ADVIA Centaur CA 125II is supplied as a reusable automated immunoassay system for use in clinical laboratories. It is not sterile and requires proper handling and maintenance per manufacturer instructions. The device is classified as Class II under FDA regulations and complies with FDA 510(k) clearance (K200199) and In Vitro Diagnostic Regulation (IVDR). Storage and operational conditions must adhere to the specified assay protocols to ensure accurate results.
Other devices from Siemens Healthcare Diagnostics
Properties
Other properties (18)
- Sterile: No
- Single Use: No
- Implantable: No
- Contains Latex: No
- Microbial Substances: No
- Self Testing: No
- Near-Patient Testing: No
- Companion Diagnostics: No
- Surgical Instrument: No
- New Device: No
- Prescription Use: No
- Over-the-Counter: No
- Convenience Kit: No
- Combination Product: No
- HCT/P: No
- Premarket Exempt: No
- Serial Number: No
- Manufacturing Date: No